As such, we do not see any incremental financial impact from [Thursday's] action. |
Boston Scientific still has much 'wood to chop' regarding the recovery of the company's cardiac rhythm management business...That said, we believe earnings power for businesses remain substantial. |
Given that the longer-term outlook for CRM is strong and the fact that underlying growth in most other businesses is unchanged, we remain optimistic about the future. As such, we view this quarter as a test of faith. |
Greater clarity regarding this transaction and future growth goals (without the Guidant acquisition) are needed, |
Greater clarity regarding this transaction and future growth goals (without the Guidant acquisition) are needed. |
If the company can expand this agreement to other markets, the opportunity could be big. |
J&J needs Guidant's deep middle-management bench and the cooperation of senior management. |
Overall, we found results in the quarter to be generally weak, but believe the strong market reaction was justified given the anticipated completion of the Guidant vascular acquisition. |
Results were dramatically lower than consensus estimates in both cases and reflect the challenges the company faces in rebuilding its CRM [cardiac rhythm management] business. |
Simply put, engineers were making decisions that senior management and physicians should have made. |
The device replacements will cause companies to forgo revenue producing replacement units in future years. |
The opportunity to expand into other markets could be significant. |
The proposed changes ... related to cardiac procedures are dramatic. |
We believe it will be critical for BSX to carefully manage its interaction with the FDA, |
We believe it will be critical for BSX to carefully manage its interaction with the FDA. |